POU2F1

Summary

POU2F1 (POU class 2 homeobox 1, HGNC:9212) is a protein-coding gene on chromosome 1q24.2, encoding POU domain, class 2, transcription factor 1 (P14859). Transcription factor that binds to the octamer motif (5’-ATTTGCAT-3’) and activates the promoters of the genes for some small nuclear RNAs (snRNA) and of genes such as those for histone H2B and immunoglobulins.

The OCT1 transcription factor was among the first identified members of the POU transcription factor family (summarized by Sturm et al., 1993 [PubMed 8314572]). Members of this family contain the POU domain, a 160-amino acid region necessary for DNA binding to the octameric sequence ATGCAAAT.

Source: NCBI Gene 5451 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 98 total
• GTEx eGene: eQTL in 5 tissues, sQTL in 3 (q < 0.05)
• ChEMBL bioactivity: 1 clinical-phase molecule tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.26 (highly constrained)
• Transcription factor: yes — 139 downstream targets (CollecTRI)
• MANE Select transcript: NM_002697
• Notable: 98 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9212
Approved symbol	POU2F1
Name	POU class 2 homeobox 1
Location	1q24.2
Locus type	gene with protein product
Status	Approved
Aliases	OCT1
Ensembl gene	ENSG00000143190
Ensembl biotype	protein_coding
OMIM	164175
Entrez	5451

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 11 protein_coding, 7 protein_coding_CDS_not_defined, 4 nonsense_mediated_decay, 1 retained_intron

MANE Select: ENST00000367866

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 5, TSL 2: 4, TSL 3: 1, TSL 4: 3, TSL 5: 3

ENST00000367866, ENST00000271411, ENST00000367862, ENST00000367865, ENST00000420254, ENST00000429375, ENST00000442313, ENST00000443275, ENST00000470928, ENST00000490100, ENST00000492850, ENST00000541643, ENST00000557909, ENST00000559038, ENST00000559648, ENST00000560232, ENST00000648671, ENST00000919744, ENST00001081728, ENST00001116420, ENST00001130364, ENST00001130365, ENST00001145603

RefSeq mRNA: 5 — MANE Select: NM_002697 NM_001198783, NM_001198786, NM_001365848, NM_001365849, NM_002697

CCDS: CCDS1259, CCDS55655, CCDS55656

Canonical transcript exons

ENST00000367866 — 16 exons

Exon	Start	End
ENSE00002572678	167220886	167220958
ENSE00003695971	167383857	167383951
ENSE00003696128	167389588	167389761
ENSE00003696516	167376029	167376155
ENSE00003697182	167371917	167372036
ENSE00003698113	167374108	167374296
ENSE00003698998	167411959	167412304
ENSE00003699179	167332470	167332535
ENSE00003699689	167401451	167401556
ENSE00003699742	167396286	167396427
ENSE00003700887	167397994	167398133
ENSE00003701549	167365467	167365567
ENSE00003701727	167399186	167399365
ENSE00003701816	167370161	167370214
ENSE00003787634	167413026	167413114
ENSE00003848463	167415500	167427340

Expression profiles

Bgee: expression breadth ubiquitous, 267 present calls, max score 96.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.4993 / max 230.9802, expressed in 1645 samples.

Highest expression (Bgee): buccal mucosa cell, secondary oocyte, sural nerve, oocyte, primordial germ cell in gonad.

Genetic regulation across tissues (GTEx eQTL / sQTL)

POU2F1 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 5 tissues and its splicing (sQTL) in 3 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

8 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Brain Cortex	sqtl	9.7e-03	-1.75	1:166884311:G:A
Brain Spinal cord cervical c-1	sqtl	1.2e-02	-1.83	1:167888809:G:GAGCTTGCAGTGAGCCGA
Whole Blood	sqtl	2.1e-02	+1.09	1:168094724:A:G
Esophagus Mucosa	eqtl	2.7e-02	+0.16	1:167670783:A:C
Colon Sigmoid	eqtl	2.8e-02	-0.33	1:166420477:G:A
Brain Cerebellum	eqtl	3.3e-02	-0.18	1:167155769:G:A
Brain Cerebellar Hemisphere	eqtl	3.5e-02	-0.15	1:167052312:G:A
Brain Cortex	eqtl	4.6e-02	+0.18	1:167606846:T:C

FANTOM5 promoters

6 alternative TSS:

Promoter ID	TPM avg	Samples expressed
6429	8.4479	1639
6435	0.6043	169
6436	0.1623	88
6434	0.1389	64
6437	0.0983	42
6438	0.0476	20

Top tissues by expression

showing 100 of 287 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	96.45	gold quality
secondary oocyte	CL:0000655	93.05	gold quality
sural nerve	UBERON:0015488	92.85	gold quality
oocyte	CL:0000023	91.29	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.86	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.59	gold quality
calcaneal tendon	UBERON:0003701	87.20	gold quality
tendon	UBERON:0000043	86.04	gold quality
cerebellar vermis	UBERON:0004720	85.25	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	84.31	gold quality
tendon of biceps brachii	UBERON:0008188	83.48	gold quality
colonic epithelium	UBERON:0000397	83.40	gold quality
bone marrow cell	CL:0002092	83.19	gold quality
medial globus pallidus	UBERON:0002477	83.08	gold quality
urethra	UBERON:0000057	82.83	gold quality
nipple	UBERON:0002030	82.51	gold quality
corpus callosum	UBERON:0002336	82.43	gold quality
globus pallidus	UBERON:0001875	82.20	gold quality
saphenous vein	UBERON:0007318	82.19	gold quality
cranial nerve II	UBERON:0000941	81.89	gold quality
sperm	CL:0000019	81.83	gold quality
bone marrow	UBERON:0002371	80.74	gold quality
vena cava	UBERON:0004087	80.32	silver quality
tibia	UBERON:0000979	80.28	gold quality
male germ cell	CL:0000015	80.17	gold quality
amniotic fluid	UBERON:0000173	80.17	gold quality
synovial joint	UBERON:0002217	80.10	gold quality
ventral tegmental area	UBERON:0002691	80.06	gold quality
cerebellum	UBERON:0002037	79.64	gold quality
blood	UBERON:0000178	79.63	gold quality
inferior vagus X ganglion	UBERON:0005363	79.59	gold quality
tonsil	UBERON:0002372	79.53	gold quality
ventricular zone	UBERON:0003053	79.35	gold quality
cartilage tissue	UBERON:0002418	79.23	gold quality
trigeminal ganglion	UBERON:0001675	79.06	gold quality
cerebellar cortex	UBERON:0002129	79.00	gold quality
mucosa of stomach	UBERON:0001199	78.93	gold quality
cerebellar hemisphere	UBERON:0002245	78.88	gold quality
subthalamic nucleus	UBERON:0001906	78.74	gold quality
Brodmann (1909) area 23	UBERON:0013554	78.72	gold quality
body of tongue	UBERON:0011876	78.64	silver quality
tibialis anterior	UBERON:0001385	78.60	silver quality
ganglionic eminence	UBERON:0004023	78.58	gold quality
middle temporal gyrus	UBERON:0002771	78.53	gold quality
renal medulla	UBERON:0000362	78.48	gold quality
pericardium	UBERON:0002407	78.48	silver quality
superior vestibular nucleus	UBERON:0007227	78.32	gold quality
trabecular bone tissue	UBERON:0002483	78.29	gold quality
superior surface of tongue	UBERON:0007371	78.21	gold quality
endothelial cell	CL:0000115	78.20	silver quality
lower lobe of lung	UBERON:0008949	78.20	gold quality
right hemisphere of cerebellum	UBERON:0014890	78.05	gold quality
embryo	UBERON:0000922	78.01	gold quality
pharyngeal mucosa	UBERON:0000355	77.95	silver quality
penis	UBERON:0000989	77.95	gold quality
deltoid	UBERON:0001476	77.94	silver quality
tongue	UBERON:0001723	77.86	silver quality
dorsal root ganglion	UBERON:0000044	77.68	gold quality
pigmented layer of retina	UBERON:0001782	77.65	gold quality
retina	UBERON:0000966	77.64	gold quality
pylorus	UBERON:0001166	77.62	gold quality
dorsal plus ventral thalamus	UBERON:0001897	77.57	silver quality
right lung	UBERON:0002167	77.45	gold quality
esophagus squamous epithelium	UBERON:0006920	77.09	gold quality
occipital lobe	UBERON:0002021	77.07	gold quality
seminal vesicle	UBERON:0000998	77.06	gold quality
adrenal tissue	UBERON:0018303	77.05	gold quality
primary visual cortex	UBERON:0002436	76.95	gold quality
trachea	UBERON:0003126	76.92	silver quality
cardia of stomach	UBERON:0001162	76.71	gold quality
gastrocnemius	UBERON:0001388	76.68	gold quality
visceral pleura	UBERON:0002401	76.68	gold quality
medulla oblongata	UBERON:0001896	76.51	gold quality
muscle of leg	UBERON:0001383	76.48	gold quality
layer of synovial tissue	UBERON:0007616	76.18	gold quality
popliteal artery	UBERON:0002250	76.12	gold quality
tibial artery	UBERON:0007610	76.12	gold quality
pancreatic ductal cell	CL:0002079	76.11	silver quality
pons	UBERON:0000988	76.00	silver quality
ovary	UBERON:0000992	76.00	gold quality
gingival epithelium	UBERON:0001949	75.95	silver quality
hindlimb stylopod muscle	UBERON:0004252	75.85	gold quality
epithelium of nasopharynx	UBERON:0001951	75.79	gold quality
monocyte	CL:0000576	75.78	gold quality
leukocyte	CL:0000738	75.77	gold quality
mononuclear cell	CL:0000842	75.77	gold quality
nasopharynx	UBERON:0001728	75.77	gold quality
entorhinal cortex	UBERON:0002728	75.73	gold quality
parietal pleura	UBERON:0002400	75.70	gold quality
pleura	UBERON:0000977	75.63	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	75.62	silver quality
tibial nerve	UBERON:0001323	75.55	gold quality
superficial temporal artery	UBERON:0001614	75.49	silver quality
subcutaneous adipose tissue	UBERON:0002190	75.48	gold quality
lateral nuclear group of thalamus	UBERON:0002736	75.47	silver quality
skeletal muscle organ	UBERON:0014892	75.47	gold quality
muscle organ	UBERON:0001630	75.46	gold quality
gingiva	UBERON:0001828	75.12	gold quality
placenta	UBERON:0001987	75.03	gold quality
myometrium	UBERON:0001296	74.99	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.54
E-MTAB-6386	no	205.16

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 78 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Hippocampal formation	tissue	23.6
Corpus callosum	tissue	21.9
Amygdala	tissue	21.8
Cerebral cortex	tissue	21.5	low
Insular cortex	tissue	21.5
Basal ganglia	tissue	21.0	low
Cerebellum	tissue	20.9	not detected
Entorhinal cortex	tissue	20.2
Retrosplenial cortex	tissue	20.1
Prefrontal cortex	tissue	20.0
Retrosplenial and cingulate cortex	tissue	19.6
Temporal cortex	tissue	19.4
Motor cortex	tissue	19.3
Septum	tissue	17.8
Occipital cortex	tissue	17.7
Periaqueductal gray	tissue	17.0
Ventral forebrain	tissue	16.8
Somatosensory cortex	tissue	16.8
Olfactory bulb	tissue	16.3
Midbrain	tissue	15.5
Thalamus	tissue	15.3
Hypothalamus	tissue	15.2
Superior colliculi	tissue	14.2
Putamen	tissue	13.8
Spinal cord	tissue	13.8
Substantia nigra	tissue	13.7
Pons	tissue	13.5
Medulla oblongata	tissue	13.5
Retina	tissue	12.0
Nucleus accumbens	tissue	8.2
Hippocampus	tissue	6.4	not detected
Postcentral gyrus	tissue	5.6
Locus coeruleus	tissue	4.9
Caudate putamen	tissue	3.9
Skeletal muscle	tissue	3.7	not detected
Bone marrow	tissue	3.7	not detected
Choroid plexus	tissue	3.6
Thymus	tissue	3.5
Parathyroid gland	tissue	3.2	medium
Tonsil	tissue	3.2	medium
Pituitary gland	tissue	3.0
Vagina	tissue	3.0	medium
Spleen	tissue	2.9	low
Skin 1	tissue	2.8	medium
Lymph node	tissue	2.8	medium
Frontal cortex	tissue	2.6
Epididymis	tissue	2.4	medium
Tongue	tissue	2.4
Placenta	tissue	2.3	high
Cervix	tissue	2.2	medium
Endometrium 1	tissue	2.2	low
Breast	tissue	2.1	medium
Thyroid gland	tissue	2.1	not detected
Appendix	tissue	2.1	medium
Testis	tissue	2.0	high
Ovary	tissue	2.0	not detected
Rectum	tissue	2.0	high
Colon	tissue	2.0	high
Kidney	tissue	2.0	high
Prostate	tissue	2.0	medium

Brain sub-regions (HPA Brain Atlas): detected in 191; highest nTPM — Subiculum (23.6), White matter (21.9), Ventral hippocampus (19.4), Dorsal hippocampus (17.4), Ventral spinal cord (13.8).

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

showing 30 of 139 targets:

Target	Regulation
ADAM2
AHSP	Unknown
ALDH3A1	Activation
AR	Unknown
ATP11C
ATP6V1E1	Activation
BCL2
BDKRB1	Unknown
CAPN6	Unknown
CAT	Activation
CCND1	Activation
CDC6	Activation
CDKN1A	Unknown
CDKN2A
CDKN2B	Unknown
CDX2	Unknown
CDX4
CNTF
CR2	Unknown
CRISP3	Repression
CRP	Unknown
CSN2	Unknown
CXCL8	Activation
CXCR5	Unknown
CYP1A1	Unknown
CYP2A6
CYP4A11	Unknown
EMC10
ESR1	Unknown
ETS1	Unknown

JASPAR motifs

Motif	Name	Family
MA0785.1	POU2F1	POU domain factors
MA0785.2	POU2F1	POU domain factors
MA1962.1	POU2F1::SOX2	POU domain factors,SOX-related factors
UN0577.1	POU2F1::DLX2	POU domain factors,NK
UN0578.1	POU2F1::ELK1	POU domain factors,Ets-related
UN0579.1	POU2F1::ETV1	POU domain factors,Ets-related
UN0579.2	POU2F1::ETV1	POU domain factors,Ets-related

JASPAR matrix evidence (PMIDs): PMID:1361172, PMID:29335749

Upstream regulators (CollecTRI, top): AP1, FOXC1, HNF1A, HNF4A, NFKB, NR0B2, PPARG, STAT3, USF1, USF2

miRNA regulators (miRDB)

Targeting POU2F1 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 473 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4455	100.00	65.48	1587
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954

Functional genomics

gnomAD constraint: pLI 1, LOEUF 0.256, missense Z 2.73 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000367866 splits into 4 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
1:167,220,898–167,371,995	161 / 147.0	1.10	no
1:167,371,996–167,389,667	163 / 214.4	0.76	no
1:167,389,668–167,399,281	95 / 195.1	0.49	no
1:167,399,282–167,415,807	319 / 386.0	0.83	no

Literature-anchored findings (GeneRIF, showing 40)

• immunodepletion of Oct-1 and NF-YA proteins or mutations in the OCT-1 and CAAT motifs disrupt BRCA1 binding to the GADD45 promoter (PMID:11777930)
• Results demonstrate that functional interaction of Oct-1 and Brn-1 with androgen receptors is determined by the precise sequence of the octamer binding site, and by differential interaction with transcriptional machinery. (PMID:11997177)
• Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors (PMID:12019209)
• Oct-1 potentiates CREB-dependent cyclin D1 transcriptional activity by a phospho-CREB and CREB binding protein-independent mechanism (PMID:12391146)
• results clearly indicate a role of octamer transcription factor-1 in the transcriptional repression of the human gonadotropin-releasing hormone receptor gene (PMID:12446597)
• Our data on the interaction of two promoters with the enhancer and silencer in different cell types point to fine tissue-specific regulation of the oct-1 gene expression, especially in lymphatic cells. (PMID:12669425)
• Selective inhibition of class switching to IGG and IgE by recruitment of this and HOXC4 proteins and Ku70/ku86 to newly identified ATTT cis-elements. (PMID:12672812)
• enhancement of transcriptional potential by OBF1 (PMID:12727885)
• transcription of the Oct-1 gene is regulated by two promoters located upstream of the exon 1U and upstream of the exon 1L (PMID:12853155)
• The Oct-1 protein has been isolated,purified and characterized functionally. Histone gene expression is dependent on OCT1 and OCA-S coactivator complex. (PMID:12887915)
• OCA-S is a multicomponent OCT1 coactivator which has been isolated and functionally characterized. (PMID:12887926)
• OCT1 and SOX2 have roles in transcriptional activation of the Oct1.Sox2.Hoxb1-DNA ternary transcription factor complex (PMID:14559893)
• Histone deacetylase inhibitors can induce Gadd45 through its promoter without the need for functional p53, and both Oct-1 and NF-Y concertedly participate in trichostatin A-induced activation of the gadd45 promoter. (PMID:14586402)
• Results suggest a mechanism for the regulation of Oct-1 in response to DNA damage through specific phosphorylation within the NH(2)-terminal transcriptional regulatory domain. (PMID:14612514)
• transcriptional regulation of the key cell cycle regulator cyclin D1 and roles of both STAT5 and Oct-1 in this process (PMID:14645506)
• Data show that Oct-1 occupies the endogenous HLA-DRA promoter when the HLA-DRA promoter is inactive in retinoblastoma protein-defective cells. (PMID:15105429)
• Oct-1 and the TALE homeodomain proteins have roles in regulating the expression of the GnRH gene in neurons (PMID:15138251)
• a multiprotein complex containing GATA-1, Oct-1, and other protein factors may contribute to the formation of a repressive chromatin structure that silences gamma-globin gene expression (PMID:15613485)
• OCT-1 binds within DHS3 to silence Fshr transcription, an activity that involves members of the GATA family (PMID:15817654)
• physical binding to the family of repeats in Epstein-Barr virus oriP by the cellular transcription factors Oct-1 and Oct-2 was demonstrated by using an electrophoretic mobility-shift assay (PMID:15831936)
• Data show that GRG proteins, including GRG5, interact with two regulators of GnRH transcription, the homeodomain proteins MSX1 and OCT1, and regulate GnRH promoter activity. (PMID:16002402)
• Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter. (PMID:16116232)
• identified an AHSP gene erythroid promoter with functionally important binding sites for GATA-1- and Oct-1-related proteins (PMID:16186125)
• the binding of Oct-1 to the T-13,910 lactase variant directs increased lactase promoter activity and this might provide an explanation for the lactase persistence phenotype in the human population (PMID:16301215)
• in the case of one non-small cell lung carcinoma line (NSCLC), Rb re-expression failed to rescue HLA-DRA inducibility despite successful re-establishment of Rb-function; this failure is traceable to the failure of Rb to rescue normal Oct-1 function (PMID:16360016)
• interleukin-6 induces Oct-1 gene expression, providing a biologically relevant means by which NF-kappaB-dependent gene expression can be selectively reverted by Oct-1 to quiescent levels (PMID:17192276)
• POU5F1 and POU2F subfamily members play a pivotal role for the FZD5 expression in undifferentiated human ES cells, fetal liver/spleen, adult colon, pancreatic islet, and diffuse-type gastric cancer (PMID:17273778)
• Oct-1 is an important transcriptional repressor for p15(INK4b) gene and the transcriptional repression of the p15(INK4b) gene by Oct-1 may be one of the regulatory mechanisms of cellular senescence. (PMID:17316622)
• The transcription factors Oct-1 and -2 inhibit and enhance, respectively, the expression of exon 1-containing transcripts and CCR5 surface levels. (PMID:17442950)
• The cytotoxicity of oxaliplatin was suggested to be affected by the levels of ATP7A and hOCT1 mRNAs. (PMID:18030470)
• Suggest that Oct-1 may play an important role in the development of primary lower extremity varicose veins. (PMID:18083338)
• LOX-1 receptor blockade abrogates oxLDL-induced oxidative DNA damage and prevents activation of the transcriptional repressor Oct-1 in human coronary arterial endothelium. (PMID:18390905)
• Oct-1 transactivates hPTTG1, and both proteins are concordantly overexpressed in endocrine tumors. (PMID:18550719)
• Testosterone represses MAFbx expression via interactions of the AR with Oct-1. (PMID:18599544)
• A functional role of PPARgamma/RXRalpha and Oct-1 in the regulation of the FABP2 gene. (PMID:18634911)
• A redox-modulated direct p38/GAPDH-Oct-1 interaction nucleates the occupancy of the H2B promoter by the OCA-S complex, in which p36/LDH plays a critical role in the hierarchical organization of the complex. (PMID:18682386)
• intersegmental transfer involves a ternary intermediate, or transition state in which the DNA-binding domains bridge two different DNA fragments simultaneously (PMID:18772384)
• Oct1 may have regulatory functions in prostate development and cancer progression. (PMID:19058140)
• O-linked N-acetylglucosamines within the second serine/threonine-rich region of Sp1 interrupts a known interaction between Sp1 and Oct1 (PMID:19070619)
• Oct-1 is involved in the regulation of CDKN1A in reponse to clinically relevant doses of ionizing radiation. (PMID:19118657)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	pou2f1b	ENSDARG00000007996
		ENSDARG00000102550
mus_musculus	Pou2f1	ENSMUSG00000026565
rattus_norvegicus	Pou2f1	ENSRNOG00000003581
drosophila_melanogaster	acj6	FBGN0000028
caenorhabditis_elegans		WBGENE00006818

Paralogs (17): POU2F2 (ENSG00000028277), POU1F1 (ENSG00000064835), POU4F3 (ENSG00000091010), POU6F2 (ENSG00000106536), POU2F3 (ENSG00000137709), POU4F2 (ENSG00000151615), POU4F1 (ENSG00000152192), HDX (ENSG00000165259), POU6F1 (ENSG00000184271), POU3F2 (ENSG00000184486), POU3F1 (ENSG00000185668), POU3F4 (ENSG00000196767), POU3F3 (ENSG00000198914), CCDC160 (ENSG00000203952), POU5F1 (ENSG00000204531), POU5F1B (ENSG00000212993), POU5F2 (ENSG00000248483)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:101898) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 15 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased embryo size	2
small liver	1
small lens	1
anemia	1
abnormal embryo development	1
absent ectoplacental cone	1
embryonic growth arrest	1
pallor	1
abnormal embryonic-extraembryonic boundary morphology	1
abnormal anterior visceral endoderm morphology	1
abnormal extraembryonic ectoderm morphology	1
embryonic lethality between implantation and placentation, complete penetrance	1
lethality throughout fetal growth and development, complete penetrance	1
embryonic lethality during organogenesis, incomplete penetrance	1
impaired erythropoiesis	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Gallus gallus	P55968	100.0%	Diamond
Pan troglodytes	Q7YR49	99.7%	Diamond
Macaca mulatta	Q28503	99.0%	Diamond
Xenopus tropicalis	Q4QQQ7	98.9%	Diamond
Xenopus laevis	Q561L5	98.9%	Diamond
Mesocricetus auratus	Q812B1	98.6%	Diamond
Oncorhynchus mykiss	Q08478	98.3%	Diamond
Oncorhynchus keta	Q91169	98.3%	Diamond
Sus scrofa	Q29087	98.1%	Diamond
Bos taurus	P10036	97.9%	Diamond
Ovis aries	P79364	97.9%	Diamond
Meleagris gallopavo	Q05749	95.9%	Diamond
Bombyx mori	Q17237	95.5%	Diamond
Canis lupus familiaris	Q9TTI7	91.8%	Diamond
Dugesia japonica	P31370	83.0%	Diamond
Drosophila virilis	Q24705	73.4%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
POU2F1-DT	ncRNA	118568815
CREG1	protein-coding	8804
CD247	protein-coding	919
LINC01363	ncRNA	101928484

Protein

Protein identifiers

POU domain, class 2, transcription factor 1 — P14859 (reviewed: P14859)

Alternative names: NF-A1, Octamer-binding protein 1, Octamer-binding transcription factor 1

All UniProt accessions (5): A0A0A0MSV5, A0A0A0MT46, A0A0C4DG88, P14859, Q16075

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that binds to the octamer motif (5’-ATTTGCAT-3’) and activates the promoters of the genes for some small nuclear RNAs (snRNA) and of genes such as those for histone H2B and immunoglobulins. Modulates transcription transactivation by NR3C1, AR and PGR. (Microbial infection) In case of human herpes simplex virus (HSV) infection, POU2F1 forms a multiprotein-DNA complex with the viral transactivator protein VP16 and HCFC1 thereby enabling the transcription of the viral immediate early genes.

Subunit / interactions. Interacts with POU2AF1; the interaction increases POU2F1 transactivation activity. Interacts with NR3C1, AR, PGR and HCFC1. (Microbial infection) Associates with the herpes simplex virus VP16-induced complex; binding to HCFC1 activates the viral transcriptional activator VP16 for association with POU2F1, to form a multiprotein-DNA complex responsible for activating transcription of the viral immediate early genes. (Microbial infection) Interacts with human herpesvirus 8 (KSHV) protein RTA/ORF50; this interaction enhances RTA/ORF50-mediated transactivation of several viral promoters including K-bZIP promoter.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous. Isoform 2 is lymphocyte-specific.

Post-translational modifications. Phosphorylated by PRKDC.

Similarity. Belongs to the POU transcription factor family. Class-2 subfamily.

Isoforms (6)

UniProt ID	Names	Canonical?
P14859-1	1	yes
P14859-2	2, Oct-1L, lymphocyte-specific
P14859-3	3
P14859-6	6
P14859-4	4
P14859-5	5

RefSeq proteins (5): NP_001185712, NP_001185715, NP_001352777, NP_001352778, NP_002688* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000327	POU_dom	Domain
IPR000972	TF_octamer	Family
IPR001356	HD	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR010982	Lambda_DNA-bd_dom_sf	Homologous_superfamily
IPR013847	POU	Domain
IPR017970	Homeobox_CS	Conserved_site
IPR045703	POU2F1_C	Domain
IPR050255	POU_domain_TF	Family

Pfam: PF00046, PF00157, PF19536

UniProt features (37 total): helix 9, splice variant 6, compositionally biased region 5, modified residue 5, region of interest 5, sequence conflict 2, chain 1, domain 1, DNA-binding region 1, sequence variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

8 structures by resolution:

PDB	Title	Method	Resolution (Å)
1E3O	Crystal structure of Oct-1 POU dimer bound to MORE	X-RAY DIFFRACTION	1.9
1GT0	Crystal structure of a POU/HMG/DNA ternary complex	X-RAY DIFFRACTION	2.6
1HF0	Crystal structure of the DNA-binding domain of Oct-1 bound to DNA as a dimer	X-RAY DIFFRACTION	2.7
1OCT	CRYSTAL STRUCTURE OF THE OCT-1 POU DOMAIN BOUND TO AN OCTAMER SITE: DNA RECOGNITION WITH …	X-RAY DIFFRACTION	3
1CQT	CRYSTAL STRUCTURE OF A TERNARY COMPLEX CONTAINING AN OCA-B PEPTIDE, THE OCT-1 POU DOMAIN …	X-RAY DIFFRACTION	3.2
1O4X	TERNARY COMPLEX OF THE DNA BINDING DOMAINS OF THE OCT1 AND SOX2 TRANSCRIPTION FACTORS …	SOLUTION NMR
1POG	SOLUTION STRUCTURE OF THE OCT-1 POU-HOMEO DOMAIN DETERMINED BY NMR AND RESTRAINED …	SOLUTION NMR
1POU	THE SOLUTION STRUCTURE OF THE OCT-1 POU-SPECIFIC DOMAIN REVEALS A STRIKING SIMILARITY TO …	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P14859-F1	50.69	0.17

Human Protein Atlas

Protein class: Predicted intracellular proteins, Transcription factors, Helix-turn-helix domains, Essential proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm; endoplasmic reticulum; vesicles

Antibody reliability (HPA): IH supported · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5)

Type	Positions
Phosphothreonine	270, 276
Phosphoserine	283, 385, 448

Mutagenesis-validated functional residues (1)

Position	Phenotype
385	loss of inhibition of dna binding.

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 16; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

16 pathways:

ID	Pathway	Evidence
R-HSA-9018519	Estrogen-dependent gene expression	curated
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	curated
R-HSA-1280215	Cytokine Signaling in Immune system	—
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	electronic
R-HSA-8939211	ESR-mediated signaling	—
R-HSA-74160	Gene expression (Transcription)	—
R-HSA-168256	Immune System	—
R-HSA-73857	RNA Polymerase II Transcription	—
R-HSA-749476	RNA Polymerase III Abortive And Retractive Initiation	electronic
R-HSA-74158	RNA Polymerase III Transcription	—
R-HSA-76046	RNA Polymerase III Transcription Initiation	—
R-HSA-76071	RNA Polymerase III Transcription Initiation From Type 3 Promoter	electronic
R-HSA-6807505	RNA polymerase II transcribes snRNA genes	electronic
R-HSA-162582	Signal Transduction	—
R-HSA-449147	Signaling by Interleukins	—
R-HSA-9006931	Signaling by Nuclear Receptors	—

MSigDB gene sets: 0 (showing top):

GO Biological Process (6): DNA-templated transcription (GO:0006351), regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of miRNA transcription (GO:1902895), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (9): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), RNA polymerase II core promoter sequence-specific DNA binding (GO:0000979), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), identical protein binding (GO:0042802), sequence-specific DNA binding (GO:0043565), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), RNA polymerase II transcription regulator complex (GO:0090575)

Reactome top-level categories

11 top-level categories:

Category	Pathways
RNA Polymerase III Transcription	2
Gene expression (Transcription)	2
Signaling by Interleukins	1
RNA Polymerase II Transcription	1
RNA Polymerase III Transcription Initiation	1
ESR-mediated signaling	1
Differentiation of T cells	1
Immune System	1
Cytokine Signaling in Immune system	1
Signaling by Nuclear Receptors	1
Signal Transduction	1

GO top-level categories

33 GO namespaces:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	4
regulation of DNA-templated transcription	3
transcription by RNA polymerase II	2
DNA-templated transcription	2
regulation of transcription by RNA polymerase II	2
positive regulation of DNA-templated transcription	2
cellular anatomical structure	2
gene expression	1
RNA biosynthetic process	1
negative regulation of RNA biosynthetic process	1
miRNA transcription	1
regulation of miRNA transcription	1
positive regulation of miRNA metabolic process	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
core promoter sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
protein binding	1
DNA binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
transcription regulator complex	1
nuclear protein-containing complex	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 10 of 19 annotations. The rest are phylogenetic / computational / electronic (IEA).

10 experimentally-supported GO terms:

GO term	NS	Evidence
negative regulation of DNA-templated transcription	BP	direct assay
positive regulation of transcription by RNA polymerase II	BP	direct assay
RNA polymerase II transcription regulator complex	CC	mutant phenotype
nucleus	CC	direct assay
DNA binding	MF	direct assay
DNA-binding transcription factor activity, RNA polymerase II-specific	MF	mutant phenotype
RNA polymerase II cis-regulatory region sequence-specific DNA binding	MF	direct assay
RNA polymerase II core promoter sequence-specific DNA binding	MF	mutant phenotype
identical protein binding	MF	physical interaction
sequence-specific DNA binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,226 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
POU2F1	HCFC2	Q9Y5Z7	763
POU2F1	HCFC1	P51610	710
POU2F1	POU2AF1	Q16633	698
POU2F1	CREB3	O43889	635
POU2F1	CREBZF	Q9NS37	603
POU2F1	GCM1	Q9NP62	515
POU2F1	DCDC2	Q9UHG0	501
POU2F1	ACOT13	Q9NPJ3	498
POU2F1	ZSCAN1	Q8NBB4	487
POU2F1	MAZ	P56270	474
POU2F1	MZF1	P28698	466
POU2F1	H2BC21	Q16778	460
POU2F1	HNF1A	P20823	445
POU2F1	FOXA1	P55317	437
POU2F1	HINFP	Q9BQA5	437

IntAct

Human interaction partners of POU2F1 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

14 partners by confidence:

Partner	Interaction type	MIscore	Records
SP1	physical association	0.720	7
SP4	physical association	0.560	5
PLK3	physical association	0.560	3
POGZ	physical association	0.560	3
TEAD1	direct interaction	0.440	1
HCFC1	physical association	0.400	1
CEBPE	physical association	0.370	1
HOXB13	physical association	0.370	1
HOXC9	physical association	0.370	1
IRF9	physical association	0.370	1
POU2AF1	physical association	0.370	1
TLX2	physical association	0.370	1
BAG2	association	0.350	1
BANF1	association	0.350	1

BioGRID (248 interactions; top human partners by supporting records): NCOR2 (Affinity Capture-Western; 6 records), BRCA1 (Co-localization; 5 records), NR3C1 (Reconstituted Complex; 5 records), SP1 (Two-hybrid; 5 records), XRCC6 (Affinity Capture-Western; 5 records), XRCC5 (Affinity Capture-Western; 4 records), CREB1 (Affinity Capture-Western; 3 records), GAPDH (Reconstituted Complex; 3 records), HCFC1 (Reconstituted Complex; 3 records), HDAC1 (Affinity Capture-Western; 3 records), HOXC4 (Reconstituted Complex; 3 records), HSPA8 (Affinity Capture-MS; 3 records), MAGEA10 (Affinity Capture-MS; 3 records), PARP1 (Far Western; 3 records), POU2AF1 (Co-crystal Structure; 3 records)

SIGNOR signaling

showing 15 of 17 signaling interactions:

A	Effect	B	Mechanism
POU2AF1	up-regulates	POU2F1	binding
POU2F1	“up-regulates quantity by expression”	HOXD10	“transcriptional regulation”
POU2F1	“up-regulates quantity by expression”	HOXD11	“transcriptional regulation”
PRKAA1	down-regulates	POU2F1	phosphorylation
PER2	“down-regulates activity”	POU2F1	binding
POU2F1	“up-regulates quantity by expression”	SNAI2	“transcriptional regulation”
POU2F1	“up-regulates quantity by expression”	TWIST1	“transcriptional regulation”
POU2F1	“up-regulates quantity by expression”	GFI1B	“transcriptional regulation”
POU2F1	“down-regulates quantity by repression”	IL4	“transcriptional regulation”
PRKDC	down-regulates	POU2F1	phosphorylation
POU2F1	“up-regulates quantity by expression”	MYH2	“transcriptional regulation”
POU2F1	“up-regulates quantity by expression”	MYH1	“transcriptional regulation”
POU2F1	“up-regulates quantity by expression”	MYH10	“transcriptional regulation”
HMGB2	“up-regulates activity”	POU2F1	binding
SNAPC	“up-regulates activity”	POU2F1	binding

Protein complexes (CORUM) (4)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

4 complexes by size:

Complex	Subunits	Members
★ NFKB1-POU2F1-POU2F2-RELA-YY1 complex	5	NFKB1, POU2F1, POU2F2, RELA, YY1
OCT1-OBF1-TLE1 complex	3	POU2AF1, POU2F1, TLE1
POU2F1-SOX2 complex	2	POU2F1, SOX2
OCT1-OBF1-DNA complex	2	POU2AF1, POU2F1

Disease & clinical

Genetic variants

Variant evidence for POU2F1: 98 ClinVar records (0 pathogenic / likely pathogenic); 7 GWAS associations.

ClinVar

98 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	63
Likely benign	3
Benign	3

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 48 predictions of 1,869):

Position(s)	Effect	Δscore	Sites
1:167332468–167332469	acceptor_loss	1.0000	5
1:167332536–167332537	donor_loss	1.0000	5
1:167365465–167365466	acceptor_loss	1.0000	6
1:167365568–167365569	donor_loss	1.0000	5
1:167370215–167370216	donor_loss	1.0000	5
1:167371902	acceptor_gain	1.0000
1:167374106–167374107	acceptor_loss	1.0000	6
1:167374297–167374298	donor_loss	1.0000	4
1:167376027–167376028	acceptor_loss	1.0000	6
1:167376156–167376157	donor_loss	1.0000	5

AlphaMissense

1,564 missense substitutions predicted likely pathogenic (of 4,934 scored), across 432 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M339	9	0.998	1.000
M313	9	0.987	1.000
M418	9	0.919	0.996
N338	8	1.000	1.000
S322	8	0.999	1.000
F329	8	0.999	1.000
N429	8	0.999	1.000
F295	8	0.998	1.000
D320	8	0.998	1.000
F321	8	0.998	1.000
S335	8	0.998	1.000
D308	8	0.997	1.000
N333	8	0.997	1.000
F336	8	0.997	1.000
F291	8	0.996	1.000
F398	8	0.987	1.000
F427	8	0.982	1.000
D352	8	0.976	0.995
S385	8	0.965	1.000
F304	8	0.963	1.000

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Liver Hepatocellular Carcinoma (TCGA)	unfavorable	0.000526

Disease associations

OMIM: gene MIM:164175 | disease phenotypes:

GWAS associations

7 associations:

Study	Trait	p-value
GCST008758_8	Pre-treatment viral load in HIV-1 infection	6e-17
GCST009798_14	Asthma	8e-11
GCST008916_65	Asthma	9e-10
GCST006627_86	Diastolic blood pressure	3e-9
GCST005175_1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes	3e-6
GCST000248_4	Liver enzyme levels	4e-6
GCST005174_38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes	7e-6

EFO canonical traits (from GWAS)

3 canonical traits:

EFO ID	Trait name
EFO:0004723	coronary artery calcification
EFO:0006336	diastolic blood pressure
EFO:0010125	viral load

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3509601 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 5,545 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

1 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL237500	LINAGLIPTIN	4	5,545

PharmGKB: 1 entry (CPIC guideline: no)

ChEMBL bioactivities

1 potent at pChembl≥5 of 3 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.00	IC50	1000	nM	CHEMBL5563848

PubChem BioAssay actives

1 with measured affinity, of 95 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-6-[4-[[(3S,5R)-3-methyl-5-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)piperazin-1-yl]methyl]triazol-2-yl]pyridine-3-carbonitrile	2077520: Inhibition of OCT1 (unknown origin)	ic50	1.0000	uM

CTD chemical–gene interactions

63 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	3
Valproic Acid	affects cotreatment, decreases expression	3
methacrylaldehyde	affects cotreatment, decreases expression, increases oxidation, increases abundance	2
bisphenol S	decreases methylation, affects cotreatment, decreases expression	2
Acrolein	affects cotreatment, decreases expression, increases oxidation, increases abundance	2
Air Pollutants	affects cotreatment, decreases expression, increases abundance, increases oxidation	2
Ozone	affects cotreatment, decreases expression, increases oxidation, increases abundance	2
Tetrachlorodibenzodioxin	decreases expression	2
aristolochic acid I	decreases expression	1
lasiocarpine	decreases expression, increases metabolic processing	1
alpha-pinene	increases abundance, affects cotreatment, decreases expression, increases oxidation	1
bisphenol A	affects cotreatment, decreases expression	1
trichostatin A	decreases expression	1
2-butenal	decreases expression	1
riddelliine	decreases expression, increases metabolic processing	1
arsenite	decreases reaction, affects binding	1
sodium arsenite	increases expression	1
cobaltous chloride	affects cotreatment, affects expression	1
coenzyme Q10	decreases reaction, increases expression	1
lead chloride	affects cotreatment, affects expression	1
cadmium sulfate	affects cotreatment, affects expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
fenbuconazole	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Arsenic Trioxide	increases expression	1
Ethanol	decreases expression	1
Vehicle Emissions	decreases expression, increases abundance	1
Cadmium	decreases expression, increases abundance	1

ChEMBL screening assays

14 unique, capped per target: 9 binding, 5 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3536917	ADMET	Drug uptake assessed as OCT1 (unknown origin)-mediated drug uptake expressed in HEK293 cells by liquid scintillation counting relative to control	Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. — *Drug Metab Dispos*
CHEMBL4809211	Binding	Inhibition of human OCT1 assessed as reduction in OCT1-mediated metformin transport at 14900 uM relative to control	Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia. — *J Med Chem*

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1YH	Abcam A-549 POU2F1 KO	Cancer cell line	Male
CVCL_D2NY	Abcam THP-1 POU2F1 KO	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for POU2F1 across ~30M SureChEMBL compounds — explore on Sugi Predict.